Northrop Grumman Corporation

(New York Stock Exchange)
Back to all articles
Bullish +58

Northrop Grumman Shares Up 28% YTD With Its Biggest Upside Not Yet in Guidance

AI-generated analysis

πŸš€ Northrop Grumman shares are up 28% year-to-date, trading above the analyst consensus target of $675.

✈️ The company signed an Air Force contract to accelerate B-21 bomber production with funding approved via reconciliation.

πŸ“… This accelerated funding is expected to ramp meaningfully in 2027 and 2028, not yet included in 2026 guidance.

πŸ’° Q4 2025 revenue reached $11.7 billion, representing a 10% year-over-year increase.

πŸ“‰ The record backlog stands at $95.7 billion as of the end of Q4 2025.

πŸ’΅ Free cash flow hit $3.3 billion, up 26% from the prior year according to updated figures.

πŸ‘©β€πŸ’Ό CEO Kathy Warden described the current defense spending environment as the most robust she has seen in her career.

βš–οΈ The B-21 acceleration deal converts a previous earnings-call promise into a signed commitment with funding secured.

πŸ“ˆ Three consecutive earnings beats follow an earlier $477 million loss provision that previously shook investor confidence.

⚠️ The Sentinel ICBM program remains a fixed-price risk due to delayed initial operating capability and cost breaches.

πŸ•³οΈ Initial operating capability for the Sentinel program has slipped to 2033 following restructuring of the milestone schedule.

🌐 Northrop Grumman currently displays a bullish social sentiment score of 63.53 driven by the new production contract.

πŸ” Wall Street views the stock as pricing in execution, with short interest rising 19% but remaining below sector average.

πŸ† Aeronautics Systems business alone grew 18% in Q4 2025, contributing significantly to overall revenue expansion.

Bullish Signals
  • Northrop Grumman signed an Air Force contract to accelerate B-21 bomber production with funding approved via reconciliation, representing unpriced upside not yet included in current guidance.
  • Q4 2025 revenue reached $11.7 billion up 9.6% year-over-year with a record backlog of $95.7 billion and free cash flow of $3.235 billion up 84%.
  • The defense spending environment is the strongest in years, validating Northrop's earnings promises after previous investor confidence shaken by a $477M loss provision has recovered.
  • Shares are up 28% year-to-date to around $735.18, already trading above the analyst consensus target of $675, indicating strong market confidence in execution before numbers arrive.
  • With three consecutive earnings beats following the B-21 loss provision, CEO Kathy Warden expressed optimism regarding the agreement with the Air Force during her Q4 earnings call.
  • The underlying business is performing well with the Aeronautics Systems business alone growing 18% in Q4 while the company maintains a bullish social sentiment score of 63.53.
  • 2026 guidance calls for $43.5-$44 billion in sales and free cash flow of $3.1-$3.5 billion with the B-21 ramp meaningfully increasing in 2027 and 2028 not yet included in current numbers.
Risk Factors
  • Northrop Grumman previously recorded a $477 million B-21 loss provision that temporarily shook investor confidence, indicating potential profitability volatility even after recent earnings beats.
  • The Sentinel ICBM program faces significant downside risk as initial operating capability has slipped to 2033 following cost breaches under the Nunn-McCurdy rules.
  • The company operates on a fixed-price model for programs like Sentinel, exposing it to margin erosion if costs exceed contracted amounts.
  • Northrop Grumman trades at 26-27x earnings, which may be elevated given the execution risk associated with upcoming production ramp-ups not yet reflected in 2026 guidance.
  • The market is currently pricing in full execution success with shares trading above analyst consensus targets of $675, leaving little room for downside surprise if contracts are delayed or financial terms fall short.
  • While revenue and free cash flow growth have been reported, the formal B-21 production-rate contract has not yet been finalized with specific financial terms this quarter as indicated by CEO Kathy Warden.
  • Short interest has risen 19% recently, suggesting a portion of market participants are positioning defensively against potential execution misses despite the bullish sentiment score.
Full Analysis
Northrop Grumman (NOC) shares have gained 28% year-to-date, reaching approximately $735.18, as the market validates recent earnings guidance with a newly signed Air Force contract accelerating B-21 bomber production. This agreement represents significant unpriced upside that will ramp meaningfully in fiscal years 2027 and 2028 but is not yet included in the company's 2026 financial guidance. The February acceleration converts prior earnings call assurances into a formal commitment, with CEO Kathy Warden noting that funding for this initiative was approved via reconciliation legislation. Consequently, while the financial impact is expected to be minimal in 2026, the contract provides long-term growth certainty ahead of the company's fiscal year-end guidance targets of $43.5 billion to $44 billion in sales and free cash flow between $3.1 billion and $3.5 billion for 2026. Recent financial performance underscores the robustness of the underlying business, with fourth-quarter revenue reaching $11.7 billion, up 9.6% year-over-year, alongside a record backlog totaling $95.7 billion. Free cash flow for the quarter stood at $3.235 billion, reflecting an 84% increase, while the Aeronautics Systems business alone grew 18%. These metrics support Warden's assertion that the defense spending environment is the most robust demand she has encountered in her career, bolstering investor confidence following earlier concerns related to a $477 million loss provision associated with the B-21 program. Despite this progress, Northrop Grumman currently trades at a valuation of 26 to 27 times earnings, exceeding the analyst consensus target of roughly $675, suggesting the market is pricing in successful execution before the underlying numbers arrive for the accelerated production ramp. However, potential risks remain centered on the Sentinel ICBM program, which faces delayed initial operating capability now pushed to 2033 following cost breaches that have triggered restructuring of its milestone schedule under Nunn-McCurdy rules. While the company views the Sentinel program as not being a near-term earnings problem, it represents a fixed-price risk category similar to the earlier B-21 loss provision that previously shook investor confidence. Northrop Grumman is currently trading above the analyst consensus target despite rising short interest of 19%, indicating a divergence between bearish sentiment and bullish fundamentals driven primarily by the new B-21 contract and record backlog. The stock maintains a high social sentiment score of 63.53 as of March 11, 2026, reflecting strong market optimism regarding its ability to deliver on these commitments and manage long-term program transitions effectively.